CXCR4 and familial pancreatic carcinoma: Another peptide antagonist to CXCR4, BL-8040 (Motixafortide), has recently been tested in pancreatic cancer as a means of mobilizing bone marrow immune cells to enhance efficacy of the immune checkpoint inhibitor pembrolizumab [315].